modelN01AH01
Extends from Pharmacokinetic.Models.PK_3C.
Information
| name: | Fentanyl | |
| ATC code: | N01AH01 | route: | intravenous |
| compartments: | 3 | |
| dosage: | 0.005 | mg |
| volume of distribution: | 4 | L |
| clearance: | 40 | mL/min/kg |
| other parameters in model implementation | ||
Fentanyl is a potent synthetic opioid analgesic, primarily used in anesthesia and for managing severe pain. It acts mainly as a μ-opioid receptor agonist, providing profound analgesia and sedation. Fentanyl is approved and widely used today both in acute settings (e.g., perioperative, ICU) and for chronic pain, often as transdermal patches or intravenous injections.
Pharmacokinetics
Healthy adult volunteers, both sexes, aged approx. 20-40 years, after single intravenous dose.
References
Ziesenitz, VC, et al., & van den Anker, JN (2018). Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clinical pharmacokinetics 57(2) 125–149. DOI:10.1007/s40262-017-0569-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28688027
Smith, HAB, et al., & Berkenbosch, JW (2022). 2022 Society of Critical Care Medicine Clinical Practice Guidelines on Prevention and Management of Pain, Agitation, Neuromuscular Blockade, and Delirium in Critically Ill Pediatric Patients With Consideration of the ICU Environment and Early Mobility. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 23(2) e74–e110. DOI:10.1097/PCC.0000000000002873 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35119438
Saari, TI, et al., & Dale, O (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clinical pharmacokinetics 63(4) 397–422. DOI:10.1007/s40262-024-01355-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38485851
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.Volume | Vdp2 (from PK_3C) | Vdp2PerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | Vdp2PerKg (from PK_3C) | 0.9 | Volume of distribution peripheral 2 (l/kg) |
| Pharmacolibrary.Types.VolumeFlowRate | k13 (from PK_3C) | 1 | intercompartmental 1-3 clearance (l/min) |
| Pharmacolibrary.Types.VolumeFlowRate | k31 (from PK_3C) | 1 | intercompartmental 3-1 clearance (l/min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) | ||
| Interfaces.ConcentrationPort_b | perihperal2Cport (from PK_3C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral2 (from PK_3C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral1 (from PK_3C) | ||
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer1 (from PK_3C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)